NRXP - NRx Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Wilmington,
United States
Type: Equity
NRXP price evolution
NRXP
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.65 | $1.9 | $1.32 | $4.59 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $4.11 | $4.88 | $3.35 | $6.88 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $4.46 | $5.26 | $3.79 | $7.32 |
| Current liabilities | ||||
| Accounts payable | $4.87 | $5.01 | $6.26 | $4.63 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $20.3 | $23.66 | $18.86 | $19.05 |
| Long term debt | $2.98 | |||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $23.28 | $23.66 | $18.86 | $19.05 |
| Shareholders' equity | ||||
| Retained earnings | -$269.19 | -$267.57 | -$259.68 | -$253.15 |
| Other shareholder equity | -$0 | -$0 | -$0 | |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.59 | $20.05 | $27.61 | $0 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $6.88 | $25.8 | $32.71 | $0.08 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $5.97 | |||
| Total investments | ||||
| Total assets | $7.32 | $25.82 | $32.73 | $6.05 |
| Current liabilities | ||||
| Accounts payable | $4.63 | $2.08 | $3.69 | $0.61 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $19.05 | $15.59 | $11.92 | $1.26 |
| Long term debt | $2.82 | $2.67 | ||
| Total noncurrent liabilities | $2.67 | |||
| Total debt | ||||
| Total liabilities | $19.05 | $18.41 | $11.92 | $3.94 |
| Shareholders' equity | ||||
| Retained earnings | -$253.15 | -$223 | -$183.24 | -$0.72 |
| Other shareholder equity | -$0 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $3.02 | $7.05 | $6 | $4.41 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.01 | $0.01 | -$0.2 | -$0.01 |
| Net income | ||||
| Net income | -$1.62 | -$7.9 | -$6.53 | -$4.34 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $27.59 | $44.34 | $94.42 | $0.91 |
| Operating income | -$0.91 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.02 | |||
| Interest expense | $0.37 | $0.5 | $1.67 | |
| Net income | ||||
| Net income | -$30.16 | -$39.75 | -$93.06 | -$1.09 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $5.59 | $3.54 | $0.4 | $6.2 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.95 | -$2.7 | -$3.28 | -$15.46 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$1.09 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$0.6 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0 | -$0.01 | -$0.01 | $26.18 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $6.2 | $32.21 | $63.46 | -$25.58 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$15.46 | -$7.55 | $25.75 | $0 |
News
|
Best Momentum Stocks to Buy for January 6th
Zacks · via Yahoo Finance
6 Jan 2025
|
|
Best Momentum Stocks to Buy for December 30th
Zacks · via Yahoo Finance
30 Dec 2024
|
|
New Strong Buy Stocks for December 30th
Zacks · via Yahoo Finance
29 Dec 2024
|
|
New Strong Buy Stocks for December 26th
Zacks · via Yahoo Finance
26 Dec 2024
|
|
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
Zacks via Yahoo Finance
19 Apr 2024
|
|
Nasdaq Down 0.5%; Lithium Americas Shares Slide - D.R. Horton (NYSE:DHI), AGBA Group Holding...
Benzinga
18 Apr 2024
|
|
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In...
Benzinga
18 Apr 2024
|
|
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket By Benzinga
Investing.com
18 Apr 2024
|
|
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
Rome Sentinel
17 Apr 2024
|
|
New Strong Buy Stocks for April 4th
Zacks via Yahoo Finance
4 Apr 2024
|
Fundamentals
| Market cap | $48.45M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 11.37M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$20.39M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -2.38 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.14 |
| EPS | -$1.79 |
|---|---|
| ROA | -391.55% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.20 |
| Quick ratio | N/A |